# Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Source: https://onco.cc/trials/nct05768529/  
OnCo record `nct05768529` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of U16 in non-Hodgkin lymphoma, run by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, now recruiting.

## Summary

Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT05768529 by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, with 100 participants planned, started 2023-03-28 and due to reach its primary completion in 2024-12-31. Interventions recorded: U16.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05768529
- Phase: 1/2
- Setting: A Single-arm, Open and Multicenter Phase I/II Clinical Study to Evaluate the Safety and Efficacy of U16 Injection in the Treatment of Refractory/Recurrent B-cell Non-Hodgkin's Lymphoma (r/r B-NHL)
- Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT05768529: https://clinicaltrials.gov/study/NCT05768529

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/nct05768529.json